Emergency Management of Malignancy-Associated Hypercalcemia

Area of Science:

• Oncology
• Endocrinology
• Emergency Medicine

Background:

• Malignancy-associated hypercalcemia (MAH) is the most frequent cause of hypercalcemia in emergency departments.
• MAH arises from bone metastases, vitamin D-secreting tumors, or elevated parathyroid hormone (PTH) or PTH-related protein (PTHrP).
• MAH carries a grave prognosis, with a 50% mortality rate within one month of diagnosis.

Purpose of the Study:

• To summarize the causes, prognosis, and management of malignancy-associated hypercalcemia.
• To emphasize the critical role of prompt oncology consultation in improving survival rates for MAH patients.

Main Methods:

• Review of existing literature on malignancy-associated hypercalcemia.
• Analysis of common causes, diagnostic indicators, and therapeutic strategies.
• Evaluation of prognostic factors and survival outcomes.

Main Results:

• MAH is primarily driven by bone resorption, vitamin D secretion, or hormonal dysregulation (PTH/PTHrP).
• Standard management includes hydration, bisphosphonates, and electrolyte correction.
• No current therapies have proven to reduce MAH-related mortality; they focus on patient stabilization.

Conclusions:

• Early oncology consultation is essential for treating the underlying malignancy and improving survival in MAH patients.
• While supportive care stabilizes patients, definitive treatment of the cancer is paramount.
• MAH necessitates a multidisciplinary approach involving emergency medicine, oncology, and endocrinology specialists.